NEW YORK, June 16, 2026, 18:05 EDT
- Aditxt shares last traded at about 1.1 cents, off almost 17% from the previous close. Volume was close to 929 million shares.
- HRT Financial LP, disclosed as holding 10%, bought 4.25 million Aditxt shares at $0.016 each.
- Nasdaq compliance continues to be the main overhang. Aditxt has pointed to a planned $150 million Ignite Proteomics deal.
Aditxt Inc. shares dropped in late U.S. action Tuesday, trading a little over a penny. New ownership filings hit as volume picked up again in one of the cheapest healthcare stocks on Nasdaq.
The stock last changed hands at $0.0109, off around 17% from the previous close, after dropping to an intraday low of $0.0086. Trading volume hit almost 929 million shares. That’s unusually high for most small healthcare names, though the tiny price means even modest dollar flows push share counts up.
ADTX is trading on more than just drug or diagnostics updates now. The stock is also reacting to questions about its Nasdaq listing, its ability to raise cash, and whether the planned Ignite Proteomics spin-out will mean anything for common shareholders.
Nasdaq staff moved to delist Aditxt after the stock stayed under $1 for 30 business days, according to a May filing. The company couldn’t get an extra cure period because of its reverse-split record. Aditxt last did a reverse split at 1-for-27, with that change effective May 18.
HRT Financial LP picked up 4,252,767 shares of Aditxt at $0.016 a share on June 12, according to a new Form 4. The SEC filing listed HRT as a 10% owner. HRT’s direct stake after this trade was 2,459,308 shares.
Other new ownership filings were thinner. Bank of America Corp., Bank of America N.A. and BofA Securities Inc. put out an initial filing for 57 Aditxt shares. A later Form 4 showed seven bought and 15 sold on June 11. The firms said they weren’t admitting to being beneficial owners.
Aditxt shares slid further than most biotech names. The SPDR S&P Biotech ETF dropped roughly 0.7%. Losses in the iShares Nasdaq Biotechnology ETF were close to 0.4%. The Invesco QQQ Trust, tracking big Nasdaq names, lost about 1.9%.
Aditxt said June 9 that its main corporate push, Ignite Proteomics, struck a business combination deal valuing the unit at roughly $150 million. Ignite, which is fully owned by Aditxt and focused on functional proteomics, is supposed to spin out as a standalone public company if conditions like approvals, funding, and listing are met. Functional proteomics tests protein activity in tumor samples, instead of only sequencing genes.
Jeff Busch, who is both interim chief executive at Aditxt and CEO of Ignite, called the deal “an important milestone” and said a separate listing should give Ignite more “access to capital.” Aditxt said Ignite is focusing now on breast cancer, with plans to move into other tumor types. BusinessWire
Ignite steps into a crowded space, going up against bigger cancer diagnostics names. Guardant Health sells cancer blood tests. Abbott is the new owner of Exact Sciences’ cancer testing, which covers screening and precision oncology.
The trade could still turn against investors. In its May 29 filing, Aditxt said it failed Nasdaq’s stockholders’ equity rule and did not meet Nasdaq’s market value or net income standards. The company flagged that delisting would hit liquidity, the share price and its ability to raise cash. The Ignite deal also comes with conditions, like getting shareholder, financing and exchange-listing approvals. That leaves the stock subject to deal and listing risk.
